Evotec SE

EVO

Offer Price Offer Size 3-Year Outlook Volatility 1st Day Turnover
$21.75 20,000,000 Positive High 20.47%

Offering Team

Deal Managers

  • Bank of America Merrill Lynch
  • Morgan Stanley
  • Citigroup

Lawyers

  • Kirkland & Ellis LLP

Auditors

  • Ernst & Young GmbH Wirtschaftsprfungsgesellschaft

Pre-IPO Investors

Investors

  • Google Ventures
  • Intel Ventures
  • Patricoff Ventures
  • Kleiner Perkins

Pre-IPO Holdings(%)

  • 30
  • 20
  • 05
  • 18

Deal Highlights

We are an industry-leading drug discovery and development partner for the pharmaceutical and biotechnology industry. Our mission is to discover best and first-in-class medicines for a broad range of difficult to treat diseases in collaboration with our partners. To that end, we have built a comprehensive suite of fully integrated, next generation technology platforms which we believe will transform the way new drugs are discovered. By leveraging the advanced capabilities of o More

Deal Tracker

Investors

Filing

28 Oct, 2021

Offer

04 Nov, 2021

Look Ahead

Lock Up Expiry

04 May, 2022

Earning

Nov 1, 2018

IPO Terms

Offer Price $21.75
Offer Size 20M

Market Sentiments

Stock Price